Nektar reports REZOLVE-AD Phase 2b data showing asthma improvements with rezpegaldesleukin

NEKTAR THERAPEUTICS

Respegaldesleukin achieved statistically significant ACQ-5 reductions vs placebo in patients with AD and asthma (p<0.05).
In uncontrolled asthma subset (ACQ-5≥1.5, n=25), all doses showed significant ACQ-5 improvement; placebo-adjusted reductions 1.0–1.4.
Placebo crossover (n=42) at week 24: EASI-75 60%, vIGA-AD 0/1 33%, EASI-90 37%, Itch NRS response 50%.
Data support 24 μg/kg q2w dose with 24-week induction period for Phase 3 studies.
Top-line Phase 2b data in alopecia areata expected December 2025.

item 7.01 item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001213900-25-107821
form_type: 8-K
ticker: NKTR
cik: 0000906709
company_name: NEKTAR THERAPEUTICS
filed_at: 2025-11-10T23:59:59+00:00
discovered_at: 2026-05-14T18:02:42.555428+00:00
generated_at: 2026-05-16T22:49:49.580266+00:00
sec_items: ["7.01", "8.01", "9.01"]
event_type: other_material
sentiment: neutral
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001213900-25-107821
json_url: https://secwatch.observer/filing/0001213900-25-107821.json
markdown_url: https://secwatch.observer/filing/0001213900-25-107821.md
text_url: https://secwatch.observer/filing/0001213900-25-107821.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/906709/000121390025107821/0001213900-25-107821-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/906709/000121390025107821/ea0264736-8k_nektar.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Comparable filings

CSR

Centerspace approves $240-245M asset sales; exits Bismarck and Rapid City

CENTERSPACE June 1, 2026, 4:30 PM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

DBX

Dropbox secures $400M revolving credit facility, authorizes $900M share repurchase program

DROPBOX, INC. June 1, 2026, 9:06 AM ET other_material Items 1.01, 2.03, 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

NXTC

NextCure Phase 1 SIM0505 data: 55% ORR in gynecologic cancers; cash into Q1 2027

NextCure, Inc. June 1, 2026, 8:10 AM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

JBIO

Jade Biosciences reports Phase 1 interim data: JADE101 shows ~70% IgA reduction, favorable safety, differentiated PK

Jade Biosciences, Inc. June 1, 2026, 7:55 AM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

MVIS

MicroVision seeks reverse stock split approval; ratio 1:5 to 1:15; annual meeting July 10, 2026

MICROVISION, INC. June 1, 2026, 5:02 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

AIB

Blockchain Digital signs 15-yr, 65 MW electric agreement at CLT-01; 25 MW LOIs in pipeline

BlockchAIn Digital Infrastructure, Inc. June 1, 2026, 4:57 PM ET other_material Items 1.01, 7.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

VDTA

Vertical Data launches Vertical Edge, a direct-ownership edge data center platform

Vertical Data Inc. June 1, 2026, 4:47 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

AII

American Integrity fully places 2026-2027 CAT XOL reinsurance with $2.99B total limit

American Integrity Insurance Group, Inc. June 1, 2026, 4:31 PM ET other_material Items 7.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

Source: SEC EDGAR

accession 0001213900-25-107821

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.